Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Environ Toxicol ; 39(5): 2927-2936, 2024 May.
Article in English | MEDLINE | ID: mdl-38303669

ABSTRACT

Macrophages play an important role in defending the body against invading pathogens. In the face of pathogens, macrophages become activated and release toxic materials that disrupt the pathogens. Macrophage overactivation can lead to severe illness and inflammation. Wogonin has several therapeutic effects, including anti-inflammatory, anticancer, antioxidant, and neuroprotective effects. No studies have investigated the cytotoxic effects of wogonin at concentrations of more than 0.1 mM in RAW264.7 cells. In this study, RAW 264.7 cells were treated with wogonin, which, at concentrations of more than 0.1 mM, had cytotoxic and genotoxic effects in the RAW264.7 cells, leading to apoptosis and necrosis. Further, wogonin at concentrations of more than 0.1 mM induced caspase-3, caspase-8, and caspase-9 activation and mitochondrial dysfunction and death receptor expression. These results suggest that wogonin induces apoptosis through upstream intrinsic and extrinsic pathways by exhibiting cytotoxic and genotoxic effects.


Subject(s)
Apoptosis , Flavanones , Flavanones/pharmacology , Macrophages , DNA Damage
2.
Medicine (Baltimore) ; 95(14): e3282, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27057892

ABSTRACT

Chronic kidney disease (CKD) is a major health problem worldwide because of the aging population and lifestyle changes. One of the important etiologies of CKD is diabetes mellitus (DM). The long-term effects of pay-for-performance (P4P) on disease progression have not been thoroughly examined.This study is a retrospective population-based patient cohort design to examine the continuous effects of diabetes and CKD P4P interventions. This study used the health insurance claims database to conduct a longitudinal analysis. A total of 32,084 early CKD patients with diabetes were extracted from the outpatient claims database from January 2011 to December 2012, and the follow-up period was extended to August 2014. A 4-group matching design, including both diabetes and early CKD P4P interventions, with only diabetes P4P intervention, with only early CKD P4P intervention, and without any P4P interventions, was performed according to their descending intensity. The primary outcome of this study was all-cause mortality and the causes of death. The statistical methods included a Chi-squared test, ANOVA, and multi-variable Cox regression models.A dose-response relationship between the intervention groups and all-cause mortality was observed as follows: comparing to both diabetes and early CKD P4P interventions (reference), hazard ratio (HR) was 1.22 (95% confidence interval [CI], 1.00-1.50) for patients with only a diabetes P4P intervention; HR was 2.00 (95% CI, 1.66-2.42) for patients with only an early CKD P4P intervention; and HR was 2.42 (95% CI, 2.02-2.91) for patients without any P4P interventions. The leading cause of death of the total diabetic nephropathy patient cohort was infectious diseases (34.32%) followed by cardiovascular diseases (17.12%), acute renal failure (1.50%), and malignant neoplasm of liver (1.40%).Because the earlier interventions have lasting long-term effects on the patient's prognosis regardless of disease course, an integrated early intervention plan is suggested in future care plan designs. The mechanisms regarding the effects of P4P intervention, such as health education on diet control, continuity of care, and practice guidelines and adherence, are the primary components of disease management programs.


Subject(s)
Diabetic Nephropathies/therapy , Disease Progression , Early Medical Intervention , Reimbursement, Incentive , Renal Insufficiency, Chronic/therapy , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Time Factors
3.
Int Immunopharmacol ; 15(1): 106-13, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23142091

ABSTRACT

The hepatoprotective effects of an aqueous extract formula (AEF) derived from Artemisia capillaris, Lonicera japonica and Silybum marianum (ratio 1:1:1) were evaluated by its antioxidant properties and its attenuation of carbon tetrachloride (CCl(4))-induced liver damage in rats. The antioxidant analyses revealed that the AEF showed higher 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical and superoxide anion radical scavenging activities as well as ferric reducing antioxidant potential (FRAP) and Trolox equivalent antioxidant capacity (TEAC) compared with the individual herbs, suggesting a synergism in antioxidation between the three herbs. The animal experiments showed that the CCl(4) treatment increased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, but decreased triglyceride (TG) and glutathione (GSH) levels as well as glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) activities. However, AEF administration can successfully lower serum ALT and AST activities, restore the GSH level, ameliorate or restore GPx and CAT activities as well as improve SOD action depending on AEF dosage. Histological examination of liver showed that CCl(4) increased the extent of bile duct proliferation, necrosis, fibrosis and fatty vacuolation throughout the liver, but AEF can improve bile duct proliferation, vacuolation and fibrosis, and restore necrosis. The present study demonstrated the hepatoprotective potential of AEF as an alternative to the traditional silymarin.


Subject(s)
Antioxidants/therapeutic use , Artemisia , Chemical and Drug Induced Liver Injury/drug therapy , Drugs, Chinese Herbal/therapeutic use , Lonicera , Silybum marianum , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Carbon Tetrachloride , Catalase/metabolism , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/pathology , Drug Therapy, Combination , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Male , Phytotherapy , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/metabolism , Triglycerides/blood
4.
Pharm Biol ; 49(4): 437-44, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21388234

ABSTRACT

CONTEXT: Cynanchum taiwanianum T. Yamaza (Asclepiadaceae) is a medicinal herb used in folk medicine for the treatment of several inflammation-related diseases such as hepatitis and dermatitis in Taiwan. OBJECTIVE: In the present study, we investigated the anti-inflammatory effect of C. taiwanianum T. Yamaza rhizome aqueous extract (CTAE). MATERIALS AND METHODS: The present study investigated the anti-inflammatory effect of CTAE using IL-1ß-induced NRK-52E cells. Production of NO and PGE(2) by ELISA, the mRNA and protein expression of iNOS and COX-2, phosphorylation of IκBα, and activation of NF-κB by RT-PCR and western blotting were determined. RESULTS: The CTAE significantly (P < 0.05) inhibited NO and PGE(2) production (decreased by 46.1% and 51%, respectively), and also significantly (P < 0.05) attenuated protein and mRNA expression of iNOS and COX-2 (decreased by 90% and 55% for iNOS and by 72% and 74%% for COX-2, respectively) in IL-1ß-induced NRK-52E cells, in a dose-dependent manner, without obvious cytotoxic effects. Furthermore, the CTAE suppressed the NF-κB nuclear translocation, in terms of inhibition of IκBα phosphorylation. DISCUSSION AND CONCLUSION: Our results provided evidence for its folkloric uses and suggest that the anti-inflammatory activities of CTAE may result from the inhibition of inflammatory mediators, such as NO and PGE(2), and an upstream suppression of a NF-κB-dependent mechanism, might be involved.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cynanchum , Interleukin-1beta/metabolism , NF-kappa B/antagonists & inhibitors , Phytotherapy , Plant Extracts/pharmacology , Animals , Anti-Inflammatory Agents/toxicity , Cell Survival/drug effects , Dinoprostone/antagonists & inhibitors , Kidney/drug effects , Medicine, Traditional , Nitrous Oxide/antagonists & inhibitors , Nuclear Proteins/analysis , Phosphorylation/drug effects , Plant Extracts/toxicity , Plants, Medicinal , Rats , Rhizome
5.
Pharm Biol ; 48(2): 221-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20645845

ABSTRACT

This study evaluates the possible potency of the anti-hyperlipidemic effect of spider brake [(Pteris multifida Poiret (Pteridaceae)]. We investigated this by feeding the hyperlipidemic Sprague-Dawley rats, caused by a high cholesterol diet, with lyophilized powder of spider brake (LSB) and compared the result with the rats fed with beta-sitosterol. The results indicated that the administration of lyophilized powder of spider brake (LSB) lowered the hyperlipidemic level on rats. The relative weights of the liver, adipose tissue, and relative adipose tissue of 10% substitutions of LSB group (LSB-10) showed a significant decrease (P < 0.05) by 6%, 15.9%, and 14.3% in contrast to the untreated counterparts (control), respectively. A significantly lower (P < 0.05) plasma TG, low density lipoprotein cholesterol, low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio, liver CH, and TG contents were also observed in LSB-10 compared to the untreated counterparts (by 36.8%, 21%, 18.7%, 10.2% and 14.3% reduction, respectively). Simultaneously, the wet fecal weight, dry fecal weight, nitrogen compounds, excretion of neutral steroids, and bile acids significantly (P < 0.05) increased by 9.6%, 10.6%, 23.7%, 9.7%, and 3.4% respectively. The results showed that LSB could cause not only a reduction in CH and TG, but also could increase the excretion of lipids and metabolic by-products via the intestinal tract.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Hyperlipidemias/prevention & control , Hypolipidemic Agents/therapeutic use , Plant Extracts/therapeutic use , Pteris/chemistry , Adipose Tissue/drug effects , Adipose Tissue/pathology , Adiposity/drug effects , Animals , Bile Acids and Salts/analysis , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/chemistry , Feces/chemistry , Hyperlipidemias/chemically induced , Hyperlipidemias/metabolism , Hyperlipidemias/pathology , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/chemistry , Lipid Metabolism/drug effects , Lipids/blood , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Nitrogen/analysis , Organ Size/drug effects , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Powders , Random Allocation , Rats , Rats, Sprague-Dawley , Sterols/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...